Spero Therapeutics Operating Income Over Time
| SPRO Stock | USD 2.30 0.10 4.17% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Spero Therapeutics Performance and Spero Therapeutics Correlation. Will Biotechnology sector continue expanding? Could Spero diversify its offerings? Factors like these will boost the valuation of Spero Therapeutics. If investors know Spero will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Spero Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.753 | Earnings Share (0.79) | Revenue Per Share | Quarterly Revenue Growth (0.60) | Return On Assets |
Understanding Spero Therapeutics requires distinguishing between market price and book value, where the latter reflects Spero's accounting equity. The concept of intrinsic value - what Spero Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Spero Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Spero Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spero Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Spero Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Spero Therapeutics and related stocks such as Seres Therapeutics, VistaGen Therapeutics, and Actuate Therapeutics Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCRB | (3 M) | (3 M) | (3 M) | (6.1 M) | (15.1 M) | (54.9 M) | (92.8 M) | (91.4 M) | (100.3 M) | (71.9 M) | (88.1 M) | (64.5 M) | (179.9 M) | (195.1 M) | (121.3 M) | (109.2 M) | (114.6 M) |
| VTGN | (4.8 K) | (9 M) | (6.8 M) | (5 M) | (6.8 M) | (17.9 M) | (10.2 M) | (14.2 M) | (24.6 M) | (20 M) | (17.9 M) | (47.8 M) | (59.3 M) | (33 M) | (56 M) | (50.4 M) | (47.9 M) |
| ACTU | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (20.2 M) | (25 M) | (25.2 M) | (22.6 M) | (23.8 M) |
| INO | (6.9 M) | (21.6 M) | (23.5 M) | (19.5 M) | (39.5 M) | (34.3 M) | (76.2 M) | (83.6 M) | (94.1 M) | (111.1 M) | (124.1 M) | (301.2 M) | (267.6 M) | (143.9 M) | (112.4 M) | (101.2 M) | (96.1 M) |
| ABOS | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.8 M) | (7.9 M) | (19.6 M) | (45.2 M) | (61.1 M) | (114 M) | (102.6 M) | (97.5 M) |
| SEER | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (6.8 M) | (16.9 M) | (33.6 M) | (71.7 M) | (98 M) | (104.9 M) | (100.1 M) | (90.1 M) | (94.6 M) |
| CGTX | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.4 M) | (28.6 M) | (43.6 M) | (50.7 M) | (54 M) | (48.6 M) | (51 M) |
| IRD | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (20 M) | (22.7 M) | 18.2 M | (10.6 M) | (62.1 M) | (55.9 M) | (53.1 M) |
| HURA | (5.6 K) | (18.9 K) | (6.3 M) | (6.3 M) | (4.7 M) | (6.2 M) | (8.3 M) | (11.2 M) | (8.4 M) | (8.1 M) | (21.6 M) | (7.3 M) | (9.9 M) | (29.8 M) | (17.6 M) | (15.9 M) | (15.1 M) |
| CRBP | (824) | (824) | (824) | (557.3 K) | (2.6 M) | (8.9 M) | (20 M) | (32.6 M) | (56.7 M) | (77.1 M) | (122.8 M) | (56 M) | (34.8 M) | (45.1 M) | (48.7 M) | (43.8 M) | (46 M) |
Spero Therapeutics and related stocks such as Seres Therapeutics, VistaGen Therapeutics, and Actuate Therapeutics Operating Income description
Operating Income is the amount of profit realized from Spero Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Spero Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Spero Therapeutics | SPRO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 675 Massachusetts Avenue, |
| Exchange | NASDAQ Exchange |
USD 2.3
Check out Spero Therapeutics Performance and Spero Therapeutics Correlation. To learn how to invest in Spero Stock, please use our How to Invest in Spero Therapeutics guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Spero Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.